IDO1 and neoplasm: Dai and colleagues have developed a pH/ROS dual-sensitive, degradable metal-organic framework (MOF) capable of co-delivering GOx and the IDO inhibitor 1-methyltryptophan (1-MT) for integrated tumor starvation/oxidation immunotherapy 96.